
==== Front
Sao Paulo Med J
Sao Paulo Med J
Sao Paulo Med J
São Paulo Medical Journal
1516-3180
1806-9460
Associação Paulista de Medicina - APM

12563425
10.1590/S1516-31802002000600005
Original Article
Partial HELLP Syndrome: maternal and perinatal outcome
Abbade Joelcio Francisco *
Peraçoli José Carlos *
Costa Roberto Antonio Araújo *
Calderon Iracema de Mattos Paranhos *
Borges Vera Therezinha Medeiros *
Rudge Marilza Vieira Cunha *
Address for correspondence Departamento de Ginecologia e Obstetrícia Faculdade de Medicina de Botucatu, Universidade Estadual Paulista Caixa Postal 530 Botucatu/SP - Brasil - CEP 18618-970 Tel. (+55 14) 6802-6227 E-mail: jfabbade@fmb.unesp.br
Conflict of interest: Not declared

01 11 2002
2002
120 6 180184
20 12 2001
27 5 2002
27 6 2002
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons license.
ABSTRACT

CONTEXT:

HELLP syndrome is a severe complication of pregnancy characterized by hemolysis, elevated liver enzymes and low platelet count. Some pregnant women develop just one or two of the characteristics of this syndrome, which is termed Partial HELLP Syndrome (PHS).

OBJECTIVE:

The objective of this study was to evaluate the repercussions on maternal and perinatal outcomes among women that developed PHS and to compare these women with those whose gestational hypertension or preeclampsia did not show alterations for HELLP syndrome in laboratory tests.

DESIGN:

Observational, retrospective and analytical study.

SETTING:

Maternity Department of Hospital das Clínicas, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Botucatu, São Paulo, Brazil.

SAMPLE:

Pregnant or post-delivery women who had a blood pressure elevation that was first detected after mid-pregnancy, with or without proteinuria, between January 1990 and December 1995.

MAIN MEASUREMENTS:

Analysis was made of maternal age, race, parity, hypertension classification, gestational age at the PHS diagnosis, alterations in laboratory tests for HELLP syndrome, time elapsed to discharge from hospital, maternal complications, mode of delivery, incidence of preterm birth, intrauterine growth restriction, stillborn and neonatal death.

RESULTS:

Three hundred and eighteen women were selected; forty-one women (12.9%) had PHS and 277 of them (87.1%) did not develop any of the alterations of the HELLP syndrome diagnosis. Preeclampsia was a more frequent type of hypertension in the PHS group than in the hypertension group. None of the women with isolated chronic hypertension developed PHS. The rate of cesarean delivery, eclampsia, and preterm delivery was significantly greater in the PHS group than in the hypertension group.

CONCLUSION:

We observed that aggressive procedures had been adopted for patients with PHS. These resulted in immediate interruption of pregnancy, with elevated cesarean rates and preterm delivery. Such decisions need to be reviewed, in order to reduce the cesarean rate and the incidence of preterm delivery.

RESUMO

CONTEXTO:

A síndrome HELLP é uma grave complicação da gestação caracterizada por hemólise, elevação das enzimas hepáticas e plaquetopenia. Algumas gestantes desenvolvem somente uma ou duas dessas características da síndrome HELLP. Esse quadro é denominado de síndrome HELLP parcial (SHP).

OBJETIVO:

O objetivo deste estudo foi avaliar as repercussões maternas e perinatais das mulheres que desenvolveram SHP e comparar os resultados com mulheres que tiveram hipertensão gestacional ou pré-eclâmpsia sem alterações dos exames laboratoriais para síndrome HELLP.

TIPO DE ESTUDO:

Observacional, retrospectivo e analítico.

LOCAL:

Maternidade do Hospital das Clínicas da Faculdade de Medicina de Botucatu, Uni-versidade Estadual Paulista, Botucatu, São Paulo, Brasil.

AMOSTRA:

Foram selecionadas gestantes ou puérperas que tiveram elevação dos níveis pressóricos detectada pela primeira vez após a primeira metade da gestação com ou sem proteinúria entre janeiro/1990 a dezembro/ 1995. As mulheres foram divididas em dois grupos: Grupo SHP – quando as mulheres com hipertensão arterial tinham pelo menos uma, mas não todas as alterações de exames que demonstravam hemólise, elevação das enzimas hepáticas ou plaquetopenia – e Grupo Hipertensas – pacientes com hipertensão sem alterações nos exames laboratoriais para síndrome HELLP.

PRINCIPAIS VARIÁVEIS:

Analisamos idade materna, raça, paridade, classificação da hi-pertensão, idade gestacional no diagnóstico da SHP, alterações nos exames laboratoriais para síndrome HELLP, tempo de perma-nência no hospital, complicações maternas, via de parto, incidência de prematuridade, restrição de crescimento intra-uterino, natimortos e neomortos.

RESULTADOS:

318 mulheres foram selecionadas, das quais 41 (12,9%) tiveram SHP e 277 (87,1%) não desenvolveram alterações dos exames laboratoriais que compõem o diagnóstico da síndrome HELLP. A pré-eclâmpsia foi um tipo de hipertensão mais freqüente no grupo SHP que no grupo hipertensas. Não houve pacientes com hipertensão crônica isolada que desenvolveram SHP. A taxa de cesárea, eclâmpsia e de partos prematuros foi significativamente mais freqüente no grupo SHP que no grupo hipertensas.

CONCLUSÃO:

Observamos uma conduta agres- siva nas pacientes com SHP, que resultou na interrupção imediata da gestação, com elevada taxa de cesárea e de recém-nascido pré-termo. Esta conduta deve ser revista para a redução desses índices.

KEY WORDS:

HELLP syndrome
Partial HELLP Syndrome
Preeclampsia
Maternal outcome
Perinatal outcome
PALAVRAS CHAVES:

Síndrome HELLP
Síndrome HELLP parcial
Pré-eclâmpsia
Resultados maternos
Resultados perinatais
==== Body
pmcINTRODUCTION

Hemolysis, elevated liver enzymes and low platelet count are alterations in laboratory tests that are found in pregnant or post-delivery women who have preeclampsia. The term HELLP syndrome was coined for this set of alterations by Weinstein in 1982.1 Since then many reports have been presented, but the quantification of laboratory tests has differed among them.2-15

Since Sibai2 proposed strict criteria for the diagnosis of the “true HELLP syndrome” it has been observed that many women with severe preeclampsia may have laboratory abnormalities such as isolated hemolysis or low platelet count or elevated liver enzymes, without the complete HELLP syndrome. Women with partial HELLP syndrome (PHS) should be studied and managed separately from women with HELLP syndrome or severe preeclampsia.15

The incidence of HELLP syndrome is 2 to 12%,8,11,16-21 while the incidence of PHS is unclear, but probably around 21 to 24%.15,22 There is no information about PHS incidence in Brazil.

HELLP syndrome may begin as PHS, because it is an insidious and progressive disease. This characteristic is corroborated by the different elapsed times seen in laboratory tests for its alterations and the progress of the disease. Another factor that supports this idea is that in spite of delivery being the definitive treatment for women with HELLP syndrome, the condition of some women worsens over the first 48 hours after delivery.23

The purpose of this report was to compare maternal and perinatal outcomes between women with PHS and women who had severe blood pressure elevation but normal laboratory tests for HELLP syndrome.

METHODS

This was a retrospective, observational and analytic study. It was made in the Maternity Department of a university hospital, Hospital das Clínicas of Universidade Estadual Paulista, which is a third-level public hospital located in the central region of São Paulo State, Brazil. We searched through the perinatal database of our Maternity Department for pregnant or post-delivery women who had had a blood pressure elevation that was first detected after mid-pregnancy, either with proteinuria (preeclampsia) or without it (gestational hypertension) between January 1991 and December 1995. We reviewed maternal and neonatal medical charts.

HELLP syndrome was defined by the presence of all of the three following criteria: hemolysis (characteristic peripheral blood smear, serum lactate dehydrogenase ≥ 600 U/ l, total serum bilirubin ≥ 1.2 mg/ml), elevated liver enzymes (serum aspartate aminotransferase ≥ 70 U/l), and low platelet count (< 100,000/µl). Partial HELLP syndrome (PHS) was defined by the presence of one or two features of HELLP but not the complete syndrome.15 Patients were defined as having severe hypertension according to the criteria of the National High Blood Pressure Education Program (2000).24 The patients were divided into two groups: Partial HELLP Syndrome Group (patients with PHS) and Hypertension Group (patients with severe gestational hyper- tension/preeclampsia but without alterations in laboratory tests for HELLP syndrome). Women with renal, liver or hematological disease and multiple pregnancy were excluded from the study.

Gestational age was determined by using the best-accepted obstetric criteria, including menstrual history, early clinical evaluation and ultrasonography at < 20 weeks of gestation. The classification of the hypertensive disorders of pregnancy was done according to the National High Blood Pressure Education Program (2000),24 i.e. chronic hypertension, gestational hypertension, preeclampsia/eclamp-sia, gestational hypertension or preeclampsia superimposed upon chronic hypertension. We evaluated the abnormal laboratory findings in the PHS group and the gestational age at which PHS was diagnosed. We compared the time elapsed until discharge from hospital, maternal complications (imminent eclampsia, eclampsia, abruptio placentae and maternal mortality), mode of delivery (cesarean section), preterm delivery (gestational age < 37 weeks), perinatal outcome (intrauterine growth restriction, stillborn and neonatal death).

Data are presented as incidences. Statistical comparisons were performed by χ2 analysis, Pearson χ2 analysis and exact Fisher test, as appropriate. A p value < 0.05 was considered significant. Statistical analysis was performed using the Statistical Package in Social Science for Windows® (SPSS Inc, Chicago, version 10.0).

The procedures above were in accordance with the ethical standards of the Medical Ethics Committee of our university and with the Declaration of Helsinki.25

RESULTS

During the study period, 329 patients had clinical and laboratory findings of severe hypertension. Six women were excluded from the analysis because they had complete HELLP syndrome. Three women had multiple pregnancy and two had chronic renal insufficiency, and they were also excluded.

Among the remaining 318 women, 41 (12.9%) had PHS and 277 (87.1%) had elevated blood pressure levels, clinical and laboratory findings of severe gestational hypertension (GH) or preeclampsia (PE), with normal laboratory test results for HELLP syndrome. Demographic characteristics are presented in Table 1. Most of the women were in the 19 to 34-year-old age range. White women were more frequent in both groups. Twenty-one women (51.2 %) were nullipara in the PHS group and 128 (46.2%) in the hypertension group. There was no significant difference in these variables between the groups.

Table 1 Baseline characteristics of women with partial HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) and with only hypertension, according to maternal age, race, parity and hypertension classification

 	Partial HELLP Syndrome Group	Hypertension Group	p - value	
N	%	N	%	
Maternal age (years)	0.305	
  <19	6	14.6	50	18.1	-	
  19 to 34	24	58.5	180	64.9	-	
  ≥ 35	11	26.8	47	17.0	-	
Race	0.915	
  White	33	80.5	220	79.4	-	
  Black	8	19.5	57	20.6	-	
Parity	0.858	
  Nullipara	21	51.2	131	47.3	-	
  1 to 4	18	43.9	128	46.2	-	
  ≥ 5	2	4.9	18	6.5	-	
Classification of hypertension	0.306	
  Gestational hypertension	12	29.2	103	37.2	-	
  Preeclampsia	17	41.5	82	29.6	-	
  Gestational hypertension superimposed upon chronic hypertension	8	19.5	45	16.2	-	
  Preeclampsia superimposed upon chronic hypertension	4	9.8	47	17.0	-	

Among these women, 9.8% had preeclampsia and 19.5% had gestational hypertension superimposed upon chronic hypertension. Isolated preeclampsia was more frequent in the PHS group (41.5%) than in the hypertension group (29.6%). Gestational hypertension was observed in 13 women (29.3%) in the PHS Group and 103 (37.2%) in Hypertension Group. There were no significant differences among these factors (Table 1).

PHS was diagnosed mainly in preterm pregnancies (66.7%). Twenty-two women (56.4%) had gestations of less than 34 weeks and 5 of them (12.8%) had gestations of less than 29 weeks. Of the 41 patients with PHS, 14 (34.1%) only had hemolysis, 7 (17.1%) had hemolysis and low platelet count and 5 (12.2%) had hemolysis and elevated liver enzymes. Eight women (19.5%) only had low platelet count, 4 (9.8%) had low platelet count and elevated liver enzymes. Elevated liver enzymes alone was observed in 3 patients (7.3%) (Table 2).

Table 2 Distribution of partial HELLP syndrome (PHS) group (hemolysis, elevated liver enzymes and low platelets), according to gestational age at which PHS was diagnosed and type of alterations seen in laboratory tests for HELLP syndrome

 	Partial HELLP Syndrome Group	
N	%	
Gestational age at which PHS was diagnosed	
  < 37 weeks	26	66.7	
  23 – 28 weeks	5	12.8	
  29 – 34 weeks	17	43.6	
  35 – 36 weeks	4	10.3	
Alterations seen in laboratory tests for HELLP syndrome	
  Hemolysis	14	34.1	
  Low platelet count	8	19.5	
  Elevated liver enzymes	3	7.3	
  Hemolysis + Low platelet count	7	17.1	
  Hemolysis + Elevated liver enzymes	5	12.2	
  Low platelet count + Elevated liver enzymes	4	9.8	

There was a significant difference in the length of time spent in hospital between the groups (greater than or less than four days). Thirty-six women (87.8%) with PHS and 202 of the hypertension group (74.0%) stayed in hospital for at least four days (Table 3).

Table 3 Distribution of women with partial HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) and with only hypertension, according to time elapsed to discharge from hospital, maternal complications (abruptio placentae, imminent eclampsia, eclampsia, maternal death) and mode of delivery

 	Partial HELLP Syndrome Group	Hypertension Group	p - value	
N	%	N	%	
Time elapsed to discharge from hospital	0.036	
  < 4 days	5	12.2	72	26.0	-	
  ≥ 4 days	36	87.8	205	74.0	-	
Maternal complications	-	
  Imminent eclampsia	18	43.9	95	34.9	0.153	
  Eclampsia	6	14.6	16	5.8	0.048	
  Abruptio placentae	0	0.0	13	4.7	-	
  Maternal death	0	0.0	1	0.4	-	
Mode of delivery	0.042	
  Vaginal	4	9.8	62	22.4	-	
  Cesarean	37	90.2	215	77.6	-	

There was no difference in the incidence of abruptio placentae, imminent eclampsia and maternal death. Eclampsia was more frequent in the PHS group (14.6%) than in the hypertension group (5.8%) (Table 3), with a significant difference between the two groups.

The mode of delivery is shown in Table 3. The overall cesarean delivery rate was significantly higher in the PHS group (90.2%) than in the group with normal laboratory values for HELLP syndrome (77.6%).

Despite the incidence of preterm delivery being higher in the PHS group (70.7%) than in the hypertension group (57.7%), and the incidence of stillbirths being higher in the hypertension group (5.1%) than in the PHS group (0.0%), no statistically significant difference was observed. There were no differences in the incidence of intrauterine growth restriction and neonatal death (Table 4).

Table 4 Distribution of women with partial HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) and with only hypertension, according to incidence of preterm delivery, stillborn, neonatal death and intrauterine growth restriction

 	Partial HELLP Syndrome Group	Hypertension* Group*	p - value	
N	%	N	%	
Preterm delivery	29	70.7	158	57.7	0.760	
Term delivery	12	29.3	116	42.3	 	
Neonatal death	3	7.3	24	8.8	0.309	
Stillbirth	0	0.0	14	5.1	-	
Birth live	38	92.7	236	86.1	 	
Intrauterine growth restriction	11	26.8	75	27.4	0.897	

DISCUSSION

Although the term HELLP syndrome was not coined until 1982,1 its pathological features have been recognized for at least 100 years.26 However, controversies persist regarding the diagnosis, management, and prognosis of this enigmatic disease. This uncertainty exists partly because its pathophysiological mechanism remains obscure and partly because of disagreement about the criteria used to define this syndrome.

Sibai2 defined standardized strict laboratory criteria for disease diagnosis, which have been used in this study to define the group of women with HELLP syndrome. Other, previous authors used less strict criteria, consequently including in their studies women who we would have considered to have only partial HELLP syndrome.

HELLP syndrome or PHS can be diagnosed during pregnancy or after delivery in women whose blood pressure elevation was first detected after mid-pregnancy, either with or without proteinuria. Despite many authors having shown that HELLP syndrome is a complication ofpreeclampsia or eclampsia, Sibai2 and Martin et al.23 observed that hypertension and proteinuria may be absent or only slight. Even though HELLP syndrome is considered to be a variant or an atypical variant form of severe preeclampsia, its severity is reflected in its laboratory parameters, and not in the usual clinical parameters of blood pressure and proteinuria that typically reflect preeclampsia disease se-verity.27 We observed that 48.7% of women did not have proteinuria. It confirms the idea that PHS can occur among women with gestational hypertension or gestational hypertension superimposed upon chronic hypertension. Thus, some of these patients may have a variety of signs and symptoms, none of which are diagnostic of classic severe preeclampsia.

PHS can progress to HELLP syndrome because the alterations seen in laboratory tests may take place after different elapsed times.20 Audibert et al.15 did not observe disseminated intravascular coagulation or other maternal and perinatal complications among women with PHS or severe preeclampsia. This information suggests that women with PHS have some complications but they are not as severe as in HELLP syndrome. It emphasizes the importance of recognizing HELLP syndrome as a distinct entity that is associated with serious maternal morbidity.

We believe that the management of women with PHS must be different from the management of women with severe preeclampsia or HELLP syndrome. This may be achieved by clinical management and it may not be necessary to interrupt the pregnancy, since the maternal and perinatal outcomes among women with PHS did not exhibit any differences in comparison with women with severe gestational hypertension or preeclampsia, except for the incidence of eclampsia.

Preeclampsia increases the cesarean rate, which ranges from 29.6 to 55.0%,28-32 and this incidence is always significantly higher than the incidence of cesareans among healthy pregnant women or pregnant women with isolated chronic hypertension. The cesarean rate among pregnant women with hypertension is very high in Brazil. This rate can reach 76.7%,33-35 and it is similar to the incidence in the hypertension group of our study (77.6%).

The cesarean rate in the PHS group was very high, because when the disease was diagnosed we opted for the interruption of the pregnancy, so as to avoid evolution from PHS to HELLP syndrome and worsening of the maternal and perinatal outcomes. Audibert et al.15 and Abramovici et al.22 showed elevated cesarean rates among women with PHS, 36% and 54% respectively, but these rates were lower than the rate in the PHS group in our study (90.3%). This means that we should not indicate immediate delivery by cesarean section for almost all women with PHS, but try to encourage the conservative management of these patients.

Gestational hypertension and preeclampsia must be diagnosed as soon as possible, so as to get the best maternal and perinatal outcomes. Consequently, it is recommended that all pregnant or post-delivery women with slight or severe blood pressure elevation should have a complete blood cell, platelet count and liver enzyme determination, in order to make an early diagnosis of PHS or HELLP syndrome.

CONCLUSION

HELLP syndrome in pregnant or postdelivery women with gestational hypertension or preeclampsia needs to be diagnosed as early as possible. But in cases with a diagnosis of partial HELLP syndrome, we observed that aggressive procedures had been adopted. These resulted in immediate interruption of pregnancy, with elevated cesarean rates and preterm delivery. Such decisions need to be reviewed and a management strategy of monitoring could be attempted, in order to improve perinatal and maternal outcomes.

Joelcio Francisco Abbade, MD. Disciplina de Obstetrícia, Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista (Unesp) Júlio de Mesquita Filho, Botucatu, São Paulo, Brazil.

José Carlos Peraçoli, MD. Disciplina de Obstetrícia, Departmento de Ginecologia e Obstetrícia, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista (Unesp) Júlio de Mesquita Filho, Botucatu, São Paulo, Brazil.

Roberto Antonio Araújo Costa, MD. Disciplina de Obstetrícia, Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista (Unesp) Julio de Mesquita Filho, Botucatu, Brazil.

Iracema de Mattos Paranhos Calderon, MD. Disciplina de Obstetrícia, Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista (Unesp) Julio de Mesquita Filho, Botucatu, São Paulo, Brazil.

Vera Therezinha Medeiros Borges, MD. Disciplina de Obstetrícia, Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista (Unesp) Julio de Mesquita Filho, Botucatu, São Paulo, Brazil.

Marilza Vieira Cunha Rudge, MD. Disciplina de Obstetrícia, Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista (Unesp) Julio de Mesquita Filho, Botucatu, São Paulo, Brazil.

Sources of funding: Not declared

Maternity Department of Hospital das Clínicas, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista Júlio de Mesquita Filho, Botucatu, São Paulo, Brazil.
==== Refs
REFERENCES

1 Weinstein L Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy Am J Obstet Gynecol 1982 142 159 167 7055180
2 Sibai BM The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol 1990 162 311 316 2309811
3 Oosterhof H Voorhoeve PG Aarnoudse JG Enhancement of hepatic artery resistance to blood flow in preeclampsia in presence or absence of HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) Am J Obstet Gynecol 1994 171 526 530 8059835
4 Tsatsaris V Carbonne B Dupré La Tour M Cabrol D Milliez J Is conservative treatment of HELLP syndrome safe? Eur J Obstet Gynecol Reprod Biol 1997 80 139 141
5 O'Boyle JD Magann EF Waxman E Martin JN Dexamethasone-facilitated postponement of delivery of an extremely preterm pregnancy complicated by the syndrome of hemolysis, elevated liver enzymes, and low platelets Mil Med 1999 164 316 318 10226464
6 Martin JN Rinehart BK May WL Magann EF Terrone DA Blake PG The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzymes levels, and low platelet count) syndrome classification Am J Obstet Gynecol 1999 180 1373 1384 10368474
7 Martin JN Blake PG Lowry SL Perry KG Files JC Morrison JC Pregnancy complicated by preeclampsia-eclampsia with syndrome of hemolysis, elevated liver enzymes, and low platelet count: how rapid is postpartum recovery? Obstet Gynecol 1990 76 737 741 2216215
8 MacKenna J Dover NL Brame RG Preeclampsia associated with hemolysis, elevated liver enzymes, and low platelets - an obstetric emergency? Obstet Gynecol 1983 62 751 754 6634002
9 Van Dam PA Renier M Baekelandt M Buytaert P Uyttenbroeck F Disseminated intravascular coagulation and the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia Obstet Gynecol 1989 73 97 102 2909047
10 Goodlin RC Beware the great imitator - severe preeclampsia Contemp Ob Gyn 1982 20 215 219
11 Thiagarajah S Bourgeois FJ Harbert GM Caudle MR Thrombocytopenia in preeclampsia: associated abnormalities and management principles Am J Obstet Gynecol 1984 150 1 7 6476014
12 Brazy JE Grimm JK Little VA Neonatal manifestations of severe maternal hypertension occurring before the thirty-sixth week of pregnancy J Pediatr 1982 100 265 271 7057337
13 van Pampus MG Wolf H Westenberg SM van der Post JA Bonsel GJ Treffers PE Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with preeclampsia without HELLP syndrome Eur J Obstet Gynecol Reprod Biol 1998 76 31 36 9481543
14 Aarnoudse JG Houthoff HJ Weits J Vellenga E Huisjes HJ A syndrome of liver damage and intravascular coagulation in the last trimester of normotensive pregnancy. A clinical and histopathological study Br J Obstet Gynaecol 1986 93 145 155 3511956
15 Audibert F Friedman AS Frangieh AY Sibai BM Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome Am J Obstet Gynecol 1996 175 460 464 8765269
16 Roberts WE Perry KG Woods JB Files JC Blake PG Martin JN The intrapartum platelet count in patients with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome: is it predictive of later hemorrhagic complications? Am J Obstet Gynecol 1994 171 799 804 8092232
17 Takiuti NH Kahhale S Carrara W Alves EA Zugaib M Síndrome HELLP - Resultados materno-fetais Rev Latinam Perinatol 1994 14 13 19
18 Williams KP Wilson S Ethnic variation in the incidence of HELLP syndrome in a hypertensive pregnant population J Perinat Med 1997 25 498 501 9494922
19 Santos LC Cardoso MP Carvalho MA Porto AMF Azevedo EB Mesquita C HELLP síndrome GO Atual 1997 10 20 29
20 Marchioli M Repercussões maternas e perinatais relacionadas à classificação da hipertensão arterial na gravidez [MSc dissertation] Botucatu (SP) Faculdade de Medicina da Universidade Estadual Paulista 1999
21 Parpinelli MA Silva JLP Pereira BG Amaral E Rodrigues F Torres JCC Distúrbio hipertensivo na gravidez acompanhado por síndrome HELLP Rev Bras Ginecol Obstet 1994 16 129 134
22 Abramovici D Friedman SA Mercer BM Audibert F Kao L Sibai BM Neonatal outcome in severe preeclampsia at 24 to 36 weeks’ gestation: Does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Am J Obstet Gynecol 1999 180 221 225 9914607
23 Martin JN Blake PG Perry KG McCaul JF Hess LW Martin RW The natural history of HELLP syndrome: patterns of disease progression and regression Am J Obstet Gynecol 1991 164 1500 1513 2048596
24 National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. National Institutes of Health Publication no. 00-302, originally printed 1990, revised 2000 Washington National Institutes of Health 2000
25 Assemblea Médica Mundial – Declaración de Helsinki Recomendaciones para guiar a los médicos en la investigación biomédica en seres humanos Bol Of Sanit Panam 1990 108 626 629
26 Schmorl G Pathologisch-anatomische untersuchungen über puerperal eklampsia Leipzig FCW Vogel 1893
27 Magann EF Martin JN Twelve steps to optimal management of HELLP syndrome Clin Obstet Gynecol 1999 42 532 550 10451769
28 Sibai BM Spinnato JA Watson DL Hill GA Anderson GD Pregnancy outcome in 303 cases with severe preeclampsia Obstet Gynecol 1984 64 319 325 6462561
29 Rey E Couturier A The prognosis of pregnancy in women with chronic hypertension Am J Obstet Gynecol 1994 171 410 416 8059820
30 Omu AE al-Othman S al-Falah FZ Sharma P A comparative study of obstetric outcome of patients with pregnancy induced hypertension: economic considerations Acta Obst Gynecol Scand 1996 75 443 448 8677768
31 Jain L Effect of pregnancy-induced and chronic hypertensions on pregnancy outcome J Perinatol 1997 17 425 427 9447526
32 Hartikainen A Aliharm RH Rantakallio PT A cohort stud of epidemiological associations and outcomes of pregnancies with hypertensive disorders Hipertens Pregnancy 1998 17 31 41
33 Modema MAB Hipertensão arterial na gravidez: aspectos perinatais [MSc dissertation] Sorocaba (SP) Pontifícia Universidade Católica 1993
34 Vasconcellos MJA Ritto MNG Oliveira ILC Louro EP Rocco R Resultados do protocolo de acompanhamento da gestante hipertensa Rev Ginecol Obstet 1994 5 22 28
35 Alves EA Estudo propectivo, comparativo da isradipina e atenolol no tratamento de gestantes hipertensas [PhD thesis] São Paulo (SP) Universidade de São Paulo 1998
